Brainstorm Cell Therapeutics Newsroom

Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating

Futu NewsOct 30 23:32

Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2

Futu NewsSep 26 02:32

Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2

Futu NewsAug 16 01:31

Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials

TipRanksAug 16 00:39

Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial

TipRanksJul 12 19:37

Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target

BenzingaJul 11 21:09

Brainstorm Cell Analyst Ratings

BenzingaJul 11 21:08

Brainstorm Cell Analyst Ratings

BenzingaSep 28, 2023 22:13

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksAug 16, 2023 00:35

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksJun 8, 2023 01:25

Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating

MT NewswiresMar 31, 2023 21:14

Maxim Group Maintains Buy on Brainstorm Cell, Lowers Price Target to $10

BenzingaMar 31, 2023 21:10

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Brainstorm Cell Therapeutics (BCLI) and Agilon Health (AGL)

TipRanksMar 29, 2023 20:26

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksJan 12, 2023 03:50